Sign In
Buy PACB
$1.45
-0.180 (-11.04%)
At Close: Jun 05, 2026
PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq
01:51pm, Friday, 05'th Sep 2025
PacBio collaborates with EpiCypher to integrate Fiber-Seq and HiFi sequencing, advancing single-molecule epigenomics with new chromatin mapping tools.
PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow
09:05am, Wednesday, 03'rd Sep 2025
New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer New addition to PacBio C
Pacific Biosciences of California, Inc. (PACB) Q2 2025 Earnings Call Transcript
08:18pm, Friday, 08'th Aug 2025
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Christian O. Henry - President, CEO & Director James R.
PacBio Stock Up on Q2 Earnings & Revenue Beat Estimates, Margin Rises
01:11pm, Friday, 08'th Aug 2025
PACB stock jumps after Q2 results beat estimates, with narrow losses, rising margins, and strong global demand.
Pacific Biosciences (PACB) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
08:30pm, Thursday, 07'th Aug 2025
The headline numbers for Pacific Biosciences (PACB) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Stre
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates
08:01pm, Thursday, 07'th Aug 2025
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.2 per share a year ago.
PacBio to Present at Upcoming Investor Conferences
09:00am, Wednesday, 06'th Aug 2025
MENLO PARK, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be particip
Stay Ahead of the Game With Pacific Biosciences (PACB) Q2 Earnings: Wall Street's Insights on Key Metrics
10:16am, Monday, 04'th Aug 2025
Beyond analysts' top-and-bottom-line estimates for Pacific Biosciences (PACB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for
The most comprehensive, family-based variant dataset ever published will improve variant classification using AI-based tools The most comprehensive, family-based variant dataset ever published will im
Pacific Biosciences of California (PACB) Suffers a Larger Drop Than the General Market: Key Insights
07:16pm, Tuesday, 29'th Jul 2025
Pacific Biosciences of California (PACB) reached $1.54 at the closing of the latest trading day, reflecting a -6.1% change compared to its last close.
Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing
08:52am, Tuesday, 29'th Jul 2025
New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of disease BOSTON , July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology bus
PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in Nature Communications
09:05am, Thursday, 24'th Jul 2025
Study reveals millions of previously unknown variants and genomic sequences from underrepresented populations Study reveals millions of previously unknown variants and genomic sequences from underrepr
PacBio Joins the 1000 Genomes Long Read Project to Add Isoform Sequencing with Kinnex and Revio
09:05am, Wednesday, 23'rd Jul 2025
New Iso-Seq data from ~1,000 samples to expand transcriptomic insights using highly accurate HiFi sequencing New Iso-Seq data from ~1,000 samples to expand transcriptomic insights using highly accurat
PacBio to Report Second Quarter 2025 Financial Results on August 7, 2025
04:05pm, Monday, 21'st Jul 2025
MENLO PARK, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2025 financial results on Thur
